• LAST PRICE
    5.08
  • TODAY'S CHANGE (%)
    Trending Up0.10 (2.01%)
  • Bid / Lots
    5.06/ 2
  • Ask / Lots
    5.09/ 20
  • Open / Previous Close
    4.95 / 4.98
  • Day Range
    Low 4.95
    High 5.19
  • 52 Week Range
    Low 2.60
    High 12.99
  • Volume
    74,593
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 4.98
TimeVolumeENOB
09:32 ET28994.98
09:38 ET193255.19
09:39 ET12475.04
09:41 ET2005.02
09:43 ET15005.0346
09:52 ET107685.06
09:54 ET100005.0501
09:56 ET44675.1
09:57 ET31005.1001
10:01 ET31005.1
10:06 ET4005.09
10:12 ET15005.16
10:14 ET1005.1501
10:15 ET18195.13
10:17 ET37755.12
10:19 ET7005.105
10:26 ET24005.09
10:33 ET1005.0783
10:39 ET1005.081
10:44 ET3405.07
10:55 ET32005.09
10:57 ET3005.08
Data delayed at least 15 minutes.

Jul 20, 2021

8:30AM ET on Tuesday Jul 20, 2021 by MT Newswires

7:00AM ET on Tuesday Jul 20, 2021 by Thomson Reuters ONE

Jul 12, 2021

0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesENOB
Enochian Biosciences Inc
258.7M
-17.6x
---
United StatesMBIO
Mustang Bio Inc
252.3M
-2.7x
---
United StatesTLSA
Tiziana Life Sciences PLC
190.2M
-6.7x
---
United StatesCMPX
Compass Therapeutics, Inc.
251.4M
-8.2x
---
United StatesINMB
INmune Bio Inc
268.8M
-14.2x
---
United StatesEIGR
Eiger BioPharmaceuticals Inc
270.3M
-9.3x
---
As of 2021-08-02

Company Information

Enochian Biosciences Inc, formerly DanDrit Biotech USA, Inc., is a Denmark-based biotechnology company. The Company focuses on developing vaccine against colorectal cancer. It has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac (MCV) for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark). The Company offers MCV platform technology, which is a cellular immunotherapy for treatment of cancer. Also, the Company develops gene therapies for patients with human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS).

Contact Information

Headquarters
Century City Medical Plaza 2080 Century City EastLOS ANGELES, CA, United States 90067
Phone
212-763-0184
Fax
845-818-3588

Executives

Independent Chairman of the Board
Rene Sindlev
Chief Executive Officer
Mark Dybul
Chief Financial Officer
Luisa Puche
Director
Henrik Gronfeldt-Sorensen
Independent Director
Gregg Alton

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$258.7M
Revenue (TTM)
$0.00
Shares Outstanding
52.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.29
EPS
$-0.29
Book Value
$3.58
P/E Ratio
-17.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.